Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs.

"CONFLICT OF INTEREST STATEMENT Torsten Zuberbier has received institutional funding for research and/or honoria for lectures and/or consulting from AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan, Leti, L'Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva and UCB; in addition, he is a member of ARIA/WHO, DGAKI, ECARF, GA2LEN and WAO. Lisa A. Beck has no conflict of interest to declare. Anna Bedbrook has no conflict of interest to declare. Marjolein de Bruin‐Weller has been a consultant, advisory board member and/or speaker for AbbVie, Almirall, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, Sanofi‐Genzyme and UCB. Jean Bousquet reports lecture honoraria from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi‐Aventis, Teva, Uriach; outside the submitted work, and is a shareholder of KYomed Innov and MASK‐air‐SAS. Michael Cork is an investigator and consultant for Regeneron, Sanofi Genzyme, Pfizer, Leo, Galapagos, Novartis, Boots, L'Oreal, Dermavant, Menlo, Reckitt Benckiser, Oxagen, Johnson & Johnson, Hyphens, Astellas, AbbVie, Galderma and Procter & Gamble. Nikolaos Douladiris has no conflict of interest to declare. Norito Katoh reports grants and personal fees from Mitsubishi Tanabe Pharm, Taiho Pharmaceutical, Torii Pharmaceutical, Maruho, Kyowa Kirin, Ely‐Lilly Japan, Sanofi, Jansen Pharma, Eisai, A2 Healthcare, Leo Pharma, Boehringer Ingelheim Japan, Abbvie, Celgene Japan. Charlotte G. Mortz has no conflict of interest to declare. Thomas Werfel reports grants and personal fees from Sanofi Regeneron, Leo Pharma, Ely Lilly, Abbievie, Pfizer, Almirall, Galderma, and Novartis. Francuzik Wojciech has no conflict of interest to declare. Andreas Wollenberg reports personal fees from AbbVie, Chugai, Galderma, LEO Pharma, Lilly, MedImmune, Novartis, Pfizer, Regeneron and Sanofi‐Aventis; and grants from LEO Pharma outside the submitted work. Kristina Siemens reports personal fees for medical writing from the GA2LEN ADCARE Network. Katarina Stevanovic has no conflict of interest to report. Margitta Worm reports grants and personal fees from Stallergens, HAL Allergie, Bencard Allergie, Allergopharma, ALK‐Abello, Mylan Germany, Actelion Pharmaceuticals Deutschland, Biotest, AbbVie Deutschland, Lilly Deutschland Aimmune, DBV Technologies, Regeneron Pharmaceuticals, Sanofi Aventis, Leo Pharma, Novartis and Viatris, outside the submitted work."

"The Global Allergy and Asthma European Network (GA2LEN) provided unrestricted funding to support the completion of the AD‐ICPs. Open access funding enabled and organized by Projekt DEAL."